Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | VIR |
---|---|---|
09:32 ET | 14304 | 9.2 |
09:33 ET | 3775 | 9.31 |
09:35 ET | 2936 | 9.25 |
09:37 ET | 500 | 9.265 |
09:39 ET | 13350 | 9.35 |
09:42 ET | 700 | 9.37 |
09:44 ET | 3966 | 9.3571 |
09:46 ET | 1617 | 9.3534 |
09:48 ET | 1591 | 9.36 |
09:50 ET | 2299 | 9.3543 |
09:51 ET | 819 | 9.39 |
09:53 ET | 1734 | 9.38 |
09:55 ET | 1695 | 9.4 |
10:00 ET | 7158 | 9.46 |
10:02 ET | 2960 | 9.445 |
10:04 ET | 7662 | 9.56 |
10:06 ET | 800 | 9.56 |
10:08 ET | 800 | 9.55 |
10:09 ET | 2564 | 9.52 |
10:11 ET | 1103 | 9.515 |
10:13 ET | 3271 | 9.51 |
10:15 ET | 1948 | 9.485 |
10:18 ET | 436 | 9.475 |
10:20 ET | 1277 | 9.42 |
10:22 ET | 4341 | 9.42 |
10:24 ET | 6296 | 9.41 |
10:26 ET | 100 | 9.41 |
10:27 ET | 2004 | 9.43 |
10:29 ET | 1127 | 9.4201 |
10:31 ET | 2581 | 9.42 |
10:33 ET | 890 | 9.43 |
10:36 ET | 2360 | 9.4 |
10:38 ET | 1107 | 9.39 |
10:40 ET | 7538 | 9.39 |
10:42 ET | 2096 | 9.375 |
10:44 ET | 2061 | 9.42 |
10:45 ET | 1202 | 9.44 |
10:47 ET | 1038 | 9.43 |
10:49 ET | 2600 | 9.42 |
10:51 ET | 3018 | 9.47 |
10:54 ET | 3135 | 9.41 |
10:56 ET | 600 | 9.41 |
10:58 ET | 6736 | 9.43 |
11:00 ET | 800 | 9.42 |
11:02 ET | 200 | 9.43 |
11:03 ET | 3289 | 9.41 |
11:05 ET | 2044 | 9.425 |
11:07 ET | 6634 | 9.46 |
11:09 ET | 4182 | 9.46 |
11:12 ET | 1581 | 9.45 |
11:14 ET | 9669 | 9.49 |
11:16 ET | 100 | 9.49 |
11:18 ET | 500 | 9.5 |
11:20 ET | 1464 | 9.5 |
11:21 ET | 602 | 9.5093 |
11:23 ET | 14713 | 9.55 |
11:25 ET | 31794 | 9.565 |
11:27 ET | 1040 | 9.5631 |
11:30 ET | 5545 | 9.62 |
11:32 ET | 40488 | 9.56 |
11:34 ET | 6448 | 9.57 |
11:36 ET | 2448 | 9.58 |
11:38 ET | 1110 | 9.59 |
11:39 ET | 632 | 9.58 |
11:41 ET | 600 | 9.6 |
11:43 ET | 7189 | 9.57 |
11:45 ET | 1097 | 9.59 |
11:48 ET | 500 | 9.585 |
11:50 ET | 549 | 9.585 |
11:52 ET | 1442 | 9.6 |
11:54 ET | 600 | 9.605 |
11:56 ET | 2638 | 9.595 |
11:57 ET | 3057 | 9.5687 |
11:59 ET | 2951 | 9.57 |
12:01 ET | 4962 | 9.53 |
12:03 ET | 4500 | 9.53 |
12:06 ET | 2600 | 9.53 |
12:08 ET | 4635 | 9.5 |
12:10 ET | 3182 | 9.5 |
12:12 ET | 2799 | 9.475 |
12:14 ET | 3807 | 9.47 |
12:15 ET | 3300 | 9.47 |
12:17 ET | 1744 | 9.49 |
12:19 ET | 2500 | 9.46 |
12:21 ET | 2852 | 9.465 |
12:24 ET | 700 | 9.47 |
12:26 ET | 1298 | 9.475 |
12:28 ET | 800 | 9.48 |
12:30 ET | 1997 | 9.49 |
12:32 ET | 2605 | 9.49 |
12:33 ET | 905 | 9.48 |
12:35 ET | 1200 | 9.475 |
12:37 ET | 800 | 9.48 |
12:39 ET | 1591 | 9.48 |
12:42 ET | 1570 | 9.5 |
12:44 ET | 1700 | 9.485 |
12:46 ET | 3065 | 9.465 |
12:48 ET | 200 | 9.47 |
12:50 ET | 1600 | 9.46 |
12:51 ET | 200 | 9.47 |
12:53 ET | 2391 | 9.46 |
12:55 ET | 500 | 9.47 |
12:57 ET | 1500 | 9.46 |
01:00 ET | 1756 | 9.47 |
01:02 ET | 700 | 9.48 |
01:04 ET | 600 | 9.47 |
01:06 ET | 4900 | 9.48 |
01:08 ET | 1435 | 9.45 |
01:11 ET | 265 | 9.44 |
01:13 ET | 1103 | 9.39 |
01:15 ET | 2500 | 9.39 |
01:18 ET | 1814 | 9.38 |
01:20 ET | 5301 | 9.38 |
01:22 ET | 600 | 9.36 |
01:24 ET | 977 | 9.36 |
01:26 ET | 300 | 9.355 |
01:27 ET | 559 | 9.34 |
01:29 ET | 959 | 9.345 |
01:31 ET | 1419 | 9.335 |
01:33 ET | 189 | 9.32 |
01:36 ET | 823 | 9.3 |
01:38 ET | 800 | 9.28 |
01:40 ET | 300 | 9.26 |
01:42 ET | 1732 | 9.28 |
01:44 ET | 988 | 9.27 |
01:45 ET | 1618 | 9.3 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Vir Biotechnology Inc | 1.3B | -2.4x | --- |
Immatics NV | 1.3B | -10.2x | --- |
Gyre Therapeutics Inc | 1.4B | -16.9x | --- |
Zymeworks Inc | 1.0B | -9.8x | --- |
Arcus Biosciences Inc | 1.4B | -4.9x | --- |
Ardelyx Inc | 1.4B | -18.6x | --- |
Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.3B |
---|---|
Revenue (TTM) | $78.6M |
Shares Outstanding | 136.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.47 |
EPS | $-3.92 |
Book Value | $11.80 |
P/E Ratio | -2.4x |
Price/Sales (TTM) | 16.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -774.67% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.